Efficacy of Mesoglycan in Pain Control after Excisional Hemorrhoidectomy: A Pilot Comparative Prospective Multicenter Study

Table 4

Median (IQR) VAS scores for spontaneous pain, pain after defecation, and after rectal examination at each time point and results of the mixed-effects linear (MLM) models.

Variable	All patients	Mesoglycan group	Control group	-value
Spontaneous pain—T1	3 (2–5)	3 (2–4)	4 (3–5)
(i) T2; (ii) T3; (iii) T4	3 (2–4); 2 (0–3); 0 (0–1)	3 (1–4); 1 (0–3); 0 (0–1)	3 (2–4); 2 (2–3); 0 (0–1)
Arm (mesoglycan versus control)				0.122
Pain after defecation—T2	6 (5–7)	6 (4–7)	6 (5–8)
(i) T3; (ii) T4	4 (3–5); 1 (0–2)	3 (2–5); 1 (0–2)	4 (3–5); 2 (1–3)
Arm (mesoglycan versus control)				0.138
Pain after rectal examination—T2	6 (4–8)	5 (3–7)	6 (5–8)
(i) T3; (ii) T4	4 (3–5); 1 (0–2)	4 (2–5); 1 (0–2)	5 (3–6); 2 (0–3)
Arm (mesoglycan versus control)				0.033